前列腺增生患者接受外照射放疗时以UroLift替代基准标记物
本文报告7例连续患者在前列腺癌外照射放疗(EBRT)前同时置入UroLift治疗良性前列腺增生所致梗阻性下尿路症状(LUTS)并用于EBRT靶向定位。UroLift夹具有足够不透光性使EBRT靶向可行,所有患者均完成全程放疗而无需置入基准标记物,未出现可归因于UroLift植入物或操作的并发症,放疗期间无需额外使用α受体阻滞剂。作者认为UroLift系统可作为EBRT患者的基准标记物,但夹在矢状面投影不佳,若掺入更强不透光物质将显著改善;UroLift能否显著减轻EBRT期间及之后的LUTS仍有待证实。
要点
- 7例连续患者于2015年9月至12月置入UroLift同时治疗梗阻性LUTS并为前列腺癌EBRT靶向定位。
- UroLift夹足够不透光使EBRT靶向可行,所有患者完成全程放疗且未置入基准标记物。
- 无患者出现可归因于UroLift植入物或操作的并发症,放疗期间无需额外α受体阻滞剂。
核心结论
- UroLift系统可作为接受EBRT患者的基准标记物。
- UroLift系统当前所用夹虽一般不透光,但在矢状面投影不佳,若掺入更强不透光物质将显著改善。
- UroLift系统能否显著减轻EBRT期间及之后的LUTS仍有待证实。
研究设计与样本
- 回顾7例连续患者病历,这些患者于2015年9月至12月间置入UroLift以同时治疗良性前列腺增生所致梗阻性LUTS并为前列腺癌EBRT靶向定位。
主要发现
- UroLift夹足够不透光使EBRT靶向可行。
- 所有患者均完成全程放疗而未置入基准标记物。
- 无患者出现可归因于UroLift植入物或操作的并发症。
- 无患者放疗期间需要额外α受体阻滞剂。
临床怎么用
- 作者认为UroLift系统可作为EBRT患者的基准标记物。
- 作者指出当前UroLift夹在矢状面投影不佳,若掺入更强不透光物质将显著改善。
- 作者认为UroLift能否显著减轻EBRT期间及之后的LUTS仍有待证实。
局限性
- UroLift系统当前所用夹虽一般不透光,但在矢状面投影不佳。
- UroLift系统能否显著减轻EBRT期间及之后的LUTS仍有待证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate if using a novel treatment for obstructive benign prostatic hyperplasia (UroLift) to relive lower urinary tract symptoms (LUTS) prior to external beam radiotherapy (EBRT) could also supplant the use of fiducial markers obviating the need for a second transrectal procedure while facilitating symptom-free voiding during and after EBRT a series of patients are reported on. METHODS: The medical records of 7 consecutive patients who underwent placement of UroLift for simultaneous treatment of obstructive LUTS due to benign prostatic hyperplasia and targeting of EBRT for treatment of prostate cancer between September and December of 2015 were reviewed. RESULTS: The UroLift clips were sufficiently radiopaque to make targeting possible for EBRT. All patients were able to complete a full course of radiotherapy without placement of fiducial markers. No patient experienced complications that could be attributed to the UroLift implants or procedure during their course of radiotherapy. None of the patients required additional alpha-blockers during radiation therapy. CONCLUSION: The UroLift system can serve as fiducial markers in patients undergoing EBRT. Although the current clip utilized in the UroLift system is generally radiopaque, it does not project well on the sagittal plane and would be significantly enhanced if a more strongly opaque substance was incorporated. It remains to be proven if the UroLift system can significantly reduce the symptoms of LUTS during and post EBRT.
引用
- Keehn A, Fram E, Garg M, et al. UroLift in Place of Fiducial Markers for Patients With Benign Prostatic Hyperplasia Undergoing External Beam Radiation Therapy. Urology. 2016. PMID: 27988266. doi:10.1016/j.urology.2016.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。